Compare Abercrombie & Fitch Co. (ANF) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Philip Morris International Inc. — how do they compare? Abercrombie & Fitch Co. trades at $93.42 (market cap $4.14B), while Philip Morris International Inc. trades at $181.51 (market cap $283.07B). The key difference: Philip Morris International Inc. is far larger — about 68.4× Abercrombie & Fitch Co.'s market cap, and Philip Morris International Inc. pays a 3.24% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ANF | PM | |
|---|---|---|
Market Cap | $4.14B | $283.07B |
Sector | Consumer Cyclical | Consumer Staples |
52-Week High | $129.85 | $191.86 |
52-Week Low | $65.61 | $144.33 |
Enterprise Value | $4.81B | $329.56B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
Philip Morris International (PM) trades at $181.62, up 0.25% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company maintains robust profitability with a 26.74% net income margin. However, a recent $500 million impairment charge and lowered profit guidance due to cost pressures and currency swings present near-term headwinds. The stock is near the analyst consensus price target of $194, with support at $179 and resistance at $185.
The outlook for PM is cautiously optimistic, driven by its strong brand portfolio, including IQOS, and consistent cash flow generation. Investment opportunities lie in its dividend yield and potential for margin recovery. Key risks include regulatory challenges, illicit market growth in Europe, and ongoing cost inflation. Analyst consensus remains bullish, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
